1. Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9:e026797.
2. Amin AL, Wagner JL. Contemporary management of atypical breast lesions identified on percutaneous biopsy: a narrative review. Ann Breast Surg. 2021;5:1–9 (AME Publ Co).
3. Baker JL, Bennett DL, Bonaccio E, Camp MS, Chikarmane S, Conant EF, et al. NCCN Guidelines Version 1.2022 breast cancer screening and diagnosis continue NCCN guidelines panel disclosures [Internet]. 2022 [cited 2023 Mar 17]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf
4. American Society of Breast Surgeons [Internet]. Consensus guideline on concordance assessment of image-guided breast biopsies and management of borderline or high-risk lesions. 2016 [cited 2020 Apr 26]. p. 1–12. Available from: https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf
5. Hartmann LC, Degnim AC, Saten RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast—risk assessment and management options. New Eng J Med 2015;372(1):78–89.https://doi.org/10.1056/NEJMsr1407164.